Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used...

action as a tyrosine kinase, targeted therapies (the first of which was imatinib) that specifically inhibit the activity of the BCR-ABL protein have been...

kinase. Before the 2001 U.S. Food and Drug Administration (FDA) approval of imatinib, no drugs were available to alter the natural progression of CML. Only...

patent imatinib mesylate in beta crystalline form (rather than imatinib or imatinib mesylate); thus they sought to prevent extant literature on imatinib or...

step for the development of cancer. Therefore, kinase inhibitors, such as imatinib and osimertinib, are often effective cancer treatments. Most tyrosine kinases...

exon 17 are responsible for resistance to targeted therapy drugs like imatinib mesylate, a tyrosine kinase inhibitor. KIT-p.D419del (exon 8) — A subset...

the years. However, French scientists treating leukemia patients with imatinib, a drug used in treating cancer, noted an unexpected side effect: some...

tissue. One of the most successful molecular targeted therapeutics is imatinib, marketed as Gleevec, which is a kinase inhibitor with exceptional affinity...

CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination...

Topotecan Etoposide Teniposide Tafluposide Bortezomib Erlotinib Gefitinib Imatinib Vemurafenib Vismodegib Azacitidine Azathioprine Capecitabine Cladribine...